Michael Ambrogi Net Worth

The estimated Net Worth of Michael J. Ambrogi is at least $13.4 Milione dollars as of 21 July 2020. Mr. Ambrogi owns over 46,293 units of NovoCure Ltd stock worth over $4,335,740 and over the last 9 years he sold NVCR stock worth over $4,392,698. In addition, he makes $4,676,260 as Vice President - Senior Technology Fellow at NovoCure Ltd.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Ambrogi NVCR stock SEC Form 4 insiders trading

Michael has made over 43 trades of the NovoCure Ltd stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 46,293 units of NVCR stock worth $857,809 on 21 July 2020.

The largest trade he's ever made was exercising 332,984 units of NovoCure Ltd stock on 4 January 2016 worth over $56,607. On average, Michael trades about 31,022 units every 29 days since 2015. As of 21 July 2020 he still owns at least 251,639 units of NovoCure Ltd stock.

You can see the complete history of Mr. Ambrogi stock trades at the bottom of the page.

Michael Ambrogi biography

Michael J. Ambrogi has been appointed as Vice President - Senior Technology Fellow of the Company effective 9/1/2020. He has been our Chief Operating Officer since 2010 and previously served as our U.S. General Manager from 2006 to 2010. Mr. Ambrogi has overall responsibility for our ongoing operations, engineering, manufacturing, service and human resources activities worldwide. From 1991 to 2006, Mr. Ambrogi worked for Deka Research and Development Corporation, inventor Dean Kamen’s research and development firm, last serving as general manager. Mr. Ambrogi led Deka’s teams on many products including the Baxter HomeChoice peritoneal dialysis machine, the Davol Hydroflex surgical irrigation device, the Cordis Crowne Stent and the J&J IBOT 3000 mobility system. Earlier in his career, from 1988 to 1990, Mr. Ambrogi was a consultant with McKinsey & Company, a global management consultant firm. Mr. Ambrogi holds a S.B. in mechanical engineering from MIT.

What is the salary of Michael Ambrogi?

As the Vice President - Senior Technology Fellow of NovoCure Ltd, the total compensation of Michael Ambrogi at NovoCure Ltd is $4,676,260. There are 2 executives at NovoCure Ltd getting paid more, with William Doyle having the highest compensation of $8,286,100.

How old is Michael Ambrogi?

Michael Ambrogi is 56, he's been the Vice President - Senior Technology Fellow of NovoCure Ltd since 2020. There are 16 older and 8 younger executives at NovoCure Ltd. The oldest executive at NovoCure Ltd is Prof. Yoram Palti, 83, who is the Founder & CTO.

What's Michael Ambrogi's mailing address?

Michael's mailing address filed with the SEC is C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN, PA, 19355.

Insiders trading at NovoCure Ltd

Over the last 9 years, insiders at NovoCure Ltd have traded over $237,132,855 worth of NovoCure Ltd stock and bought 164,174 units worth $2,198,429 . The most active insiders traders include Asaf Danziger, William Fwfd Ventures Fund ... e Michael J. Ambrogi. On average, NovoCure Ltd executives and independent directors trade stock every 7 days with the average trade being worth of $853,350. The most recent stock trade was executed by Ashley Cordova on 2 August 2024, trading 688 units of NVCR stock currently worth $13,856.

What does NovoCure Ltd do?

we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.

Complete history of Mr. Ambrogi stock trades at NovoCure Ltd

NovoCure Ltd executives and stock owners

NovoCure Ltd executives and other stock owners filed with the SEC include:

• William Doyle,
  Executive Chairman of the Board
• Asaf Danziger,
  President, Chief Executive Officer, Director
• Michael Ambrogi,
  Vice President - Senior Technology Fellow
• Wilhelmus Groenhuysen,
  Chief Operating Officer
• Pritesh Shah,
  Chief Commercial Officer
• Asaf Danziger,
  Pres, CEO & Director
• William F. Doyle,
  Exec. Chairman
• Wilhelmus C. M. Groenhuysen,
  Chief Operating Officer
• Todd C. Longsworth,
  Gen. Counsel
• Ashley Cordova,
  CFO & VP of Investor Relations
• Pritesh Shah,
  Chief Commercial Officer
• William Vernon,
  Lead Independent Director
• Jeryl Hilleman,
  Independent Director
• Martin Madden,
  Independent Director
• Sherilyn McCoy,
  Independent Director
• David Hung,
  Independent Director
• Kinyip Gabriel Leung,
  Independent Director
• Frank Leonard,
  Chief Development Officer
• Todd Longsworth,
  General Counsel
• Ely Benaim,
  Chief Medical Officer
• Ashley Cordova,
  Chief Financial Officer
• Dr. Ely Benaim M.D.,
  Chief Medical Officer
• Barak Ben Arye,
  Gen. Counsel
• Ingrid Goldberg,
  VP of Investor Relations
• Prof. Yoram Palti M.D., Ph.D.,
  Founder & CTO
• Uri Weinberg M.D., Ph.D.,
  Chief Science Officer
• Dr. Ely Benaim,
  Chief Medical Officer
• William Patrick Burke,
  Chief HR Officer
• Prof. Yoram Palti,
  Founder & CTO
• Timothy J Scannell,
  
• Eilon D. Kirson,
  Chief Scientific Officer
• Gert L.Volati Ltd Perlhagen,
  
• Peter M. Melnyk,
  Chief Commercial Officer
• Yoram Palti,
  Chief Technology Officer
• Charles G Iii Phillips,
  Director
• Louis J Jr Lavigne,
  Director
• Ltd Volati,
  10% owner
• William Fwfd Ventures Fund ...,
  
• Gert L. Perlhagen,
  Director
• William T. Burkoth,
  Director
• Capital Vii, L.P.Pomona Cap...,
  
• Moshe Giladi,
  Chief Science Officer
• Nicolas Leupin,
  Chief Medical Officer
• Robert J Jr Mylod,
  Director
• Timothy J. Langloss,
  Director
• Hansjoerg Wyss,
  10% owner
• Allyson J Ocean,
  
• William Patrick Burke,
  Chief Human Resources Officer
• Uri Weinberg,
  Chief Innovation Officer
• W Anthony Vernon,
  
• Kristin Stafford,
  
• Gabriel Leung,
  
• Arye Barak Ben,
  General Counsel
• Michal Nath Puri,
  Chief Human Resources Officer